Direct comparison of dietary portfolio vs statin on C-reactive protein

European Journal of Clinical Nutrition

Volumn 59, Issue 7, 2005, Pages 851-860

  Jenkins, D J A ^a,b   Kendall, Cyril W C ^a,b   Marchie, A ^a,b   Faulkner, D A ^a,b   Josse, A R ^a   Wong, J M W ^a,b   de Souza, R ^a,b   Emam, A ^a,b   Parker, T L ^a,b   Li, T J ^b   Josse, R G ^a,b   Leiter, L A ^a,b   Singer, W ^a,b   Connelly, P W ^a,b  

^a ST MICHAEL'S HOSPITAL   (Canada)

^b UNIVERSITY OF TORONTO   (Canada)

Author keywords

Almonds; Low saturated fat; National cholesterol education program diet; Plant sterols; Soy protein; Viscous dietary fiber

Indexed keywords

C REACTIVE PROTEIN; HYDROXYMETHYLGLUTARYL COENZYME A REDUCTASE INHIBITOR; MEVINOLIN; PHYTOSTEROL; SATURATED FATTY ACID; SOYBEAN PROTEIN;

ADULT; AGED; ALMOND; ARTICLE; BLOOD SAMPLING; CARDIOVASCULAR DISEASE; CLINICAL ARTICLE; CLINICAL TRIAL; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; CROSSOVER PROCEDURE; DIET SUPPLEMENTATION; DIETARY FIBER; FEMALE; HUMAN; HYPERLIPIDEMIA; LOW FAT DIET; MALE; OUTPATIENT CARE; PROTEIN BLOOD LEVEL; RANDOMIZED CONTROLLED TRIAL; RISK ASSESSMENT; STATISTICAL SIGNIFICANCE;

ADULT; AGED; BIOLOGICAL MARKERS; C-REACTIVE PROTEIN; CARDIOVASCULAR DISEASES; CHOLESTEROL; DIET, FAT-RESTRICTED; FEMALE; HUMANS; HYDROXYMETHYLGLUTARYL-COA REDUCTASE INHIBITORS; HYPERLIPIDEMIAS; INFLAMMATION; MALE; MIDDLE AGED; RISK FACTORS;

EID: 22644440367     PISSN: 09543007     EISSN: None     Source Type: Journal    
DOI: 10.1038/sj.ejcn.1602152     Document Type: Article

References (48)

1. Albert MA, Glynn RJ & Ridker PM (2003): Alcohol consumption and plasma concentration of C-reactive protein. Circulation 107, 443-447.
2. Albert MA, Glynn RJ & Ridker PM (2004): Effect of physical activity on serum C-reactive protein. Am. J. Cardiol. 93, 221-225.
3. Blok WL, Deslypere JP, Demacker PN, van der Ven-Jongekrijg J, Hectors MP, van der Meer JW & Katan MB (1997): Pro- and anti-inflammatory cytokines in healthy volunteers fed various doses of fish oil for 1 year. Eur. J. Clin. Invest. 27, 1003-1008.
4. Box GEP & Cox DR (1964): An analysis of transformation. JR. Stat. Soc. (B) 26, 211-252.
5. Ceriello A & Motz E (2004): Is oxidative stress the pathogenic mechanism underlying insulinresistance, diabetes and cardiovascular disease: the common soil hypothesis revisited. Arterioscler. Thromb. Vasc. Biol. 24, 816-823.
6. Cortellaro M, Cofrancesco E, Boschetti C, Cortellaro F, Mancini M & Mariani M (2000): Effects of fluvastatin and bezafibrate combination on plasma fibrinogen, t-plasminogen activator inhibitor and C reactive protein levels in coronary artery disease patients with mixed hyperlipidaemia (FACT study). Fluvastatin alone and in combination treatment. Thromb. Haemost. 83, 549-553.
7. Cushman M, Legault C, Barrett-Connor E, Stefanick ML, Kessler C, Judd HL, Sakkinen PA & Tracy RP (1999): Effect of postmenopausal hormones on inflammation-sensitive proteins: the Postmenopausal Estrogen/Progestin Interventions (PEPI) Study. Circulation 100, 717-722.
8. Danesh J, Wheeler JG, Hirschfield GM, Eda S, Eiriksdottir G, Rumley A, Lowe GD, Pepys MB & Gudnason V (2004): C-reactive protein and other circulating markers of inflammation in the prediction of coronary heart disease. N. Engl. J. Med. 350, 1387-1397.
9. Dangas G, Badimon JJ, Smith DA, Unger AH, Levine D, Shao JH, Meraj P, Fier C, Fallon JT & Ambrose JA (1999): Pravastatin therapy in hyperlipidemia: effects on thrombus formation and the systemic hemostatic profile. J. Am. Coll. Cardiol. 33, 1294-1304.
10. Downs JR, Clearfield M, Weis S, Whitney E, Shapiro DR, Beere PA, Langendorfer A, Stein EA, Kruyer W & Gotto Jr AM (1998): Primary prevention of acute coronary events with lovastatin in men and women with average cholesterol levels: results of AFCAPS/Tex-CAPS. Air Force/Texas Coronary Atherosclerosis Prevention Study. JAMA 279, 1615-1622.
11. Expert Panel on Detection, Evaluation, and Treatment of High Blood Cholesterol in Adults (2001): Executive summary of The Third Report of The National Cholesterol Education Program (NCEP) Expert Panel on Detection, Evaluation, and Treatment of High Blood Cholesterol In Adults (Adult Treatment Panel III). JAMA 285, 2486-2497.
12. Ford ES (1999): Body mass index, diabetes, and C-reactive protein among US adults. Diabetes Care 22, 1971-1977.
13. Foster-Powell K, Holt SH & Brand-Miller JC (2002): International table of glycemic index and glycemic load values: 2002. Am. J. Clin. Nutr. 76, 5-56.
14. Frohlich M, Sund M, Lowel H, Imhof A, Hoffmeister A & Koenig W (2003): Independent association of various smoking characteristics with markers of systemic inflammation in men. Results from a representative sample of the general population (MONICA Augsburg Survey 1994/95). Eur. Heart J. 24, 1365-1372.
15. Heart Protection Study Collaborative Group (2002): MRC/BHF Heart Protection Study of cholesterol lowering with simvastatin in 20 536 high-risk individuals: a randomised placebo-controlled trial. Lancet 360, 7-22.
16. Herrington DM, Vittinghoff E, Lin F, Fong J, Harris F, Hunninghake D, Bittner V, Schrott HG, Blumenthal RS & Levy R (2002): Statin therapy, cardiovascular events, and total mortality in the Heart and Estrogen/Progestin Replacement Study (HERS). Circulation 105, 2962-2967.
17. Jenkins DJ, Kendall CW, Connelly PW, Jackson CJ, Parker T, Faulkner D & Vidgen E (2002a): Effects of high- and low-isoflavone (phytoestrogen) soy foods on inflammatory biomarkers and proinflammatory cytokines in middle-aged men and women. Metabolism 51, 919-924.
18. Jenkins DJ, Kendall CW, Faulkner D, Vidgen E, Trautwein EA, Parker TL, Marchie A, Koumbridis G, Lapsley KG, Josse RG, Leiter LA & Connelly PW (2002b): A dietary portfolio approach to cholesterol reduction: combined effects of plant sterols, vegetable proteins, and viscous fibers in hypercholesterolemia. Metabolism 51, 1596-1604.
19. Jenkins DJ, Kendall CW, Marchie A, Parker TL, Connelly PW, Qian W, Haight JS, Faulkner D, Vidgen E, Lapsley KG & Spiller GA (2002c): Dose response of almonds on coronary heart disease risk factors: blood lipids, oxidized low-density lipoproteins, lipoprotein(a), homocysteine, and pulmonary nitric oxide: a randomized, controlled, crossover trial. Circulation 106, 1327-1332.
20. Jenkins DJ, Kendall CW, Marchie A, Faulkner DA, Wong JM, de Souza R, Emam A, Parker TL, Vidgen E, Lapsley KG, Trautwein EA, Josse RG, Leiter LA & Connelly PW (2003): Effects of a dietary portfolio of cholesterol-lowering foods vs lovastatin on serum lipids and C-reactive protein. JAMA 290, 502-510.
21. Jenkins DJ, Kendall CW, Marchie A, Faulkner D, Wong J, de Sousa R, Emam A, Parker T, Vidgen E, Trautwein E, Lapsley K, Josse RG, Leither LA, Singer W & Connelly PW (2005): Direct comparison of a dietary portfolio of cholesterol-lowering foods with a statin in hypercholesterolemic participants. Am. J. Clin. Nutr. 81, 380-387.
22. Jenkins DJ, Wolever TM, Leeds AR, Gassull MA, Haisman P, Dilawari J, Goff DV, Metz GL & Alberti KG (1978): Dietary fibres, fibre analogues, and glucose tolerance: importance of viscosity. BMJ 27, 1392-1394.
23. Kalela A, Laaksonen R, Lehtimaki T, Koivu TA, Hoyhtya M, Janatuinen T, Pollanen P, Vesalainen R, Saikku P, Knuuti J & Nikkari ST (2001): Effect of pravastatin in mildly hypercholesterolemic young men on serum matrix metalloproteinases. Am. J. Cardiol. 88, 173-175. A6.
24. Ledue TB & Rifai N (2003): Preanalytic and analytic sources of variations in C-reactive protein measurement: implications for cardiovascular disease risk assessment. Clin. Chem. 49, 1258-1271.
25. Lemieux I, Pascot A, Prud'homme D, Almeras N, Bogaty P, Nadeau A, Bergeron J & Despres JP (2001): Elevated C-reactive protein: another component of the atherothrombotic profile of abdominal obesity. Arterioscler. Thromb. Vasc. Biol. 21, 961-967.
26. Liu S, Manson JE, Buring JE, Stampfer MJ, Willett WC & Ridker PM (2002): Relation between a diet with a high glycemic load and plasma concentrations of high-sensitivity C-reactive protein in middle-aged women. Am. J. Clin. Nutr. 75, 492-498.
27. Neter J, Wasserman W & Kutner MH (1985): Applied Linear Statistical Models. IL: Irwin Homewood.
28. Ockene IS, Matthews CE, Rifai N, Ridker PM, Reed G & Stanek E (2001): Variability and classification accuracy of serial high-sensitivity C-reactive protein measurements in healthy adults. Clin. Chem. 47, 444-450.
29. Pearson TA, Mensah GA, Alexander RW, Anderson JL, Cannon 3rd RO, Criqui M, Fadl YY, Fortmann SP, Hong Y, Myers GL, Rifai N, Smith Jr SC, Taubert K, Tracy RP & Vinicor F (2003): Markers of inflammation and cardiovascular disease: application to clinical and public health practice: a statement for healthcare professionals from the Centers for Disease Control and Prevention and the American Heart Association. Circulation 107, 499-511.
30. Pischon T, Hankinson SE, Hotamisligil GS, Rifai N, Willett WC & Rimm EB (2003): Habitual dietary intake of n-3 and n-6 fatty acids in relation to inflammatory markers among US men and women. Circulation 108, 155-160.
31. Pradhan AD, Manson JE, Rossouw JE, Siscovick DS, Mouton CP, Rifai N, Wallace RB, Jackson RD, Pettinger MB & Ridker PM (2002): Inflammatory biomarkers, hormone replacement therapy, and incident coronary heart disease: prospective analysis from the Women's Health Initiative observational study. JAMA 288, 980-987.
32. Rattazzi M, Puato M, Faggin E, Bertipaglia B, Zambon A & Pauletto P (2003): C-reactive protein and interleukin-6 in vascular disease: culprits or passive bystanders? J. Hypertens. 21, 1787-1803.
33. Ridker PM, Buring JE, Shih J, Matias M & Hennekens CH (1998a): Prospective study of C-reactive protein and the risk of future cardiovascular events among apparently healthy women. Circulation 98, 731-733.
34. Ridker PM, Glynn RJ & Hennekens CH (1998b): C-reactive protein adds to the predictive value of total and HDL cholesterol in determining risk of first myocardial infarction. Circulation 97, 2007-2011.
35. Ridker PM, Hennekens CH, Rifai N, Buring JE & Manson JE (1999): Hormone replacement therapy and increased plasma concentration of C-reactive protein. Circulation 100, 713-716.
36. Ridker PM, Rifai N, Clearfield M, Downs JR, Weis SE, Miles JS & Gotto Jr AM (2001): Air Force/Texas Coronary Atherosclerosis Prevention Study Investigators. Measurement of C-reactive protein for the targeting of statin therapy in the primary prevention of acute coronary events. N. Engl. J. Med. 344, 1959-1965.
37. Ridker PM, Rifai N, Rose L, Buring JE & Cook NR (2002): Comparison of C-reactive protein and low-density lipoprotein cholesterol levels in the prediction of first cardiovascular events. N. Engl. J. Med. 347, 1557-1565.
38. Rifai N & Ridker PM (2002): Inflammatory markers and coronary heart disease. Curr. Opin. Lipidol. 13, 383-389.
39. Rifai N & Ridker PM (2003): Population distributions of C-reactive protein in apparently healthy men and women in the United States: implication for clinical interpretation. Clin. Chem. 49, 666-669.
40. Sacks FM, Tonkin AM, Shepherd J, Braunwald E, Cobbe S, Hawkins CM, Keech A, Packard C, Simes J, Byington R & Furberg CD (2000): Effect of pravastatin on coronary disease events in subgroups defined by coronary risk factors: the Prospective Pravastatin Pooling Project. Circulation 102, 1893-1900.
41. SAS Institute (1997): SAS/STAT User's Guide (ed 6.12). Cary, NC: SAS Institute.
42. Scandinavian Simvastatin Survival Study Group (1994): Randomized trial of cholesterol lowering in 4444 patients with coronary heart disease: the Scandinavian Simvastatin Survival Study (4S). Lancet 344, 1383-1389.
43. Shepherd J, Cobbe SM, Ford I, Isles CG, Lorimer AR, MacFarlane PW, McKillop JH & Packard CJ (1995): Prevention of coronary heart disease with pravastatin in men with hypercholesterolemia. West of Scotland Coronary Prevention Study Group. N. Engl. J. Med. 333, 1301-1307.
44. Tall AR (2004): C-reactive protein reassessed. N. Engl. J. Med. 350, 1450-1452.
45. The Homocysteine Studies Collaboration (2002): Homocysteine and risk of ischemic heart disease and stroke: a meta-analysis. JAMA 288, 2015-2022.
46. Tillet WS & Francis T (1930): Serological reaction in pneumonia with a non-protein somatic fraction of pneumococcus. J. Exp. Med. 52, 561-571.
47. Wolever TMS, Chiasson JL, Josse RG, Leiter LA, Maheux P, Rabasa-Lhoret R, Rodger NW & Ryan EA (2004): Effect of modifying source or amount of carbohydrate glucose and lipid control in type 2 diabetes. Can. J. Diab. 48 (Suppl 1) (CDA abstract).
48. Yudkin JS, Stehouwer CD, Emeis JJ & Coppack SW (1999): C-reactive protein in healthy subjects: associations with obesity, insulin resistance, and endothelial dysfunction: a potential role for cytokines originating from adipose tissue? Arterioscler. Thromb. Vasc. Biol. 19, 972-978.